Is Tucatinib officially launched in China? Drug purchasing channels and latest news

Tucatinib (Tucatinib) has not yet been officially launched in China, so patients in China cannot purchase the drug directly through formal channels. Since the original drug has not yet been approved by the Chinese drug regulatory agency, tucatinib cannot be included in the medical insurance system, and there is no channel for reimbursement through medical insurance. Therefore, if patients need to use tucatinib, they usually need to choose to purchase the drug cross-border or obtain the drug through overseas channels.

Currently, the original drug of tucatinib is priced higher in the European market. For example, 150mg*84European version of the original drug may cost more than 40,000 yuan per box, which is very expensive for many patients. Therefore, patients need to carefully evaluate their financial situation when purchasing and obtain drugs through other channels if conditions permit. At the same time, patients should also pay attention to ensuring the formality of the channels when purchasing drugs overseas to avoid purchasing fake and shoddy products.

For patients who want to get the drug at a lower price, there are also some generic versions of tucatinib on the market. For example, the price of a generic drug produced by a Lao pharmaceutical factory in 150mg*60 tablets is about more than 2,000 yuan. Compared with the original drug, the price is obviously much more affordable. Although generic drugs and original drugs are basically the same in terms of drug ingredients and therapeutic effects, due to possible differences in production processes and quality control, patients need to pay special attention to choosing reliable channels when purchasing.

In general, although the original drug of tucatinib has not yet been launched in China, patients can obtain the drug by purchasing it cross-border or choosing generic drugs. Due to the large price differences, patients need to choose the appropriate drug purchase channel based on their own financial status and treatment needs. In the future, if tucatinib is approved for marketing in China, patients will be able to obtain the drug more conveniently and may enjoy cost reductions brought by the medical insurance reimbursement policy.

Reference materials:https://www.tukysa.com/